Feb 14, 2020
FDA Approves Three Drugs for Nonprescription Use Through Rx-to-OTC Switch Process
Feb 06, 2020
Foamix Announces Publication of Phase 3 Studies Evaluating FMX103 for the Treatment of Papulopustular Rosacea in Journal of the American Academy of Dermatology
Feb 05, 2020
Information Update - Apotex Inc. recalls certain lots of the diabetes medication APO-Metformin ER (extended release) 500 mg tablets
Jan 16, 2020
FDA approves Ozempic® for cardiovascular risk reduction in adults with type 2 diabetes and known heart disease, updates Rybelsus® label
Jan 14, 2020
Foamix Announces AMZEEQ(TM) (minocycline) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S.
Jan 13, 2020
Breakthrough ID-Cap System from etectRx(TM) Selected to Measure Adherence to HIV Treatment in New University of Colorado Study
Jan 09, 2020
Foamix Announces AMZEEQ(TM) (minocycline) Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne
Jan 09, 2020
MYOS CEO Joseph Mannello Issues Letter to Shareholders
Jan 07, 2020
Cumberland Pharmaceuticals Announces The National Launch Of A New Caldolor Ready-To-Use Product
Dec 05, 2019
Statement from Janet Woodcock, M.D., director of FDA's Center for Drug Evaluation and Research, on impurities found in diabetes drugs outside the U.S.
Dec 04, 2019
Allergan Announces Positive Phase 3 ACHIEVE I Trial Results for Ubrogepant Published in The New England Journal of Medicine
Dec 03, 2019
Viriom Launches Reproductive Toxicity Studies for Elpida® (Elsulfavirine) Once Weekly Oral Formulation
Nov 22, 2019
Global Gout Disease Treatment Market to Surpass US$ 4,273.4 Million by 2027
Nov 15, 2019
Claim compensation in the Avandia drug Canada-wide settlement
Nov 05, 2019
FDA authorizes marketing of first next-generation sequencing test for detecting HIV-1 drug resistance mutations
Nov 04, 2019
Foamix Announces Publication of AMZEEQ(TM) (minocycline) Topical Foam Long Term Safety Data for Treatment Up to 1 Year in Journal of Clinical and Aesthetic Dermatology
Nov 01, 2019
Statement from Janet Woodcock, M.D., director of FDA's Center for Drug Evaluation and Research on new testing results, including low levels of impurities in ranitidine drugs
Oct 30, 2019
Information Update - Ranbaxy Pharmaceuticals Canada Inc. recalls prescription ranitidine products as a precaution; request to stop distribution remains in place while Health Canada continues to assess NDMA
Oct 23, 2019
Perrigo Company plc Issues Voluntary Worldwide Recall of Ranitidine Due to Possible Presence of Impurity, N-nitrosodimethylamine (NDMA) Impurity in the product
Oct 23, 2019
Duke Clinical Research Institute to Lead Pragmatic Study to Assess Effectiveness of Statins in Older Adults